In addition, the R‐CHOP‐resistant DLBCL cell line SU‐DHL‐2/R showed higher PDK4 than the R‐CHOP‐sensitive DLBCL cell line SU‐DHL‐2 at both the mRNA and protein levels, as well as rituximab‐resistant DLBCL cell line OCI‐ly8/R compared with rituximab‐sensitive DLBCL cell line OCI‐ly8 (Figure 1F,G). Here, DDIT3 is linked to diffuse large B-cell lymphoma.